The use of regional citrate anticoagulation for continuous venovenous hemodiafiltration in acute kidney injury

2008 ◽  
Vol 36 (11) ◽  
pp. 3024-3029 ◽  
Author(s):  
Marcelino S. Durão ◽  
Julio C. M. Monte ◽  
Marcelo C. Batista ◽  
Moacir Oliveira ◽  
Ilson J. Iizuka ◽  
...  
2021 ◽  
Vol 10 (19) ◽  
pp. 4491
Author(s):  
Marion Wiegele ◽  
Dieter Adelmann ◽  
Christoph Dibiasi ◽  
Andrè Pausch ◽  
Andreas Baierl ◽  
...  

Background: Current guidelines recommend the monitoring of anti-factor Xa (anti-Xa) levels to avoid an accumulation of low-molecular-weight heparins in patients with acute kidney injury, but there is no evidence on how to proceed with such monitoring during continuous renal replacement therapy. Against this background, we investigated the potential accumulation of enoxaparin administered subcutaneously for venous thromboembolism prophylaxis in critically ill patients during continuous renal replacement therapy covered by regional citrate anticoagulation. Methods: Anti-Xa levels were measured at baseline (≤12 h before renal replacement therapy) and on three consecutive days (A to C) when enoxaparin had reached trough levels. Supplementary testing included modified assays of rotational thromboelastometry known to be highly sensitive for low-molecular-weight heparins. Results: The 16 men and 13 women included were adults comparable in age, body mass index, thromboembolism risk assessment, and clinical severity of the disease. Throughout the four examinations, the median trough levels of anti-Xa remained below the detection limit of the test (<0.1 IU mL−1), with interquartile ranges of <0.1 to 0.14 IU mL−1 at baseline and <0.1 to 0.16 IU mL−1 on days A/B/C. All rotational thromboelastometry parameters of clot initiation and clot formation dynamics did not significantly change from baseline to day C. Conclusions: Neither anti-Xa levels nor modified assays of rotational thromboelastometry revealed any accumulation of enoxaparin administered for thromboprophylaxis during continuous renal replacement therapy covered by regional citrate anticoagulation. Although generally recommended in patients with acute kidney injury, monitoring of anti-Xa levels should be questioned in this defined setting.


BMJ Open ◽  
2019 ◽  
Vol 9 (1) ◽  
pp. e024411 ◽  
Author(s):  
Melanie Meersch ◽  
Mira Küllmar ◽  
Carola Wempe ◽  
Detlef Kindgen-Milles ◽  
Stefan Kluge ◽  
...  

IntroductionAcute kidney injury (AKI) is a well-recognised complication of critical illness which is of crucial importance for morbidity, mortality and health resource utilisation. Renal replacement therapy (RRT) inevitably entails an escalation of treatment complexity and increases costs for those patients with severe AKI. However, it is still not clear whether regional citrate anticoagulation or systemic heparin anticoagulation for continuous RRT (CRRT) is most appropriate. We hypothesise that, in contrast to systemic heparin anticoagulation, regional citrate anticoagulation for CRRT prolongs filter life span and improves overall survival in a 90-day follow-up period (coprimary endpoints).Methods and analysisWe will conduct a prospective, randomised, multicentre, clinical trial including up to 1450 critically ill patients with AKI requiring CRRT. We suggest to investigate the effect of regional citrate anticoagulation for CRRT as compared with systemic heparin anticoagulation. The two coprimary outcomes are filter life span and overall survival in a 90-day follow-up period. Secondary outcomes are length of stay in the intensive care unit; length of hospitalisation; duration of CRRT; recovery of renal function at days 28, 60, 90 and 1 year; requirement for RRT after days 28, 60, 90 and 1 year; 28 days, 60 days, 90 days and 1-year all-cause mortality; major adverse kidney events at days 28, 60, 90 and 1 year; bleeding complications; transfusion requirements; infection rate and costs of RRT. Additionally, in an add-on study involving several of the participating centres, blood samples from recruited patients will be collected at different time points to analyse whether the anticoagulation strategy has an impact on immune response as evidenced by leucocyte recruitment and function.Ethics and disseminationThe RICH trial has been approved by the Federal Institute for Drugs and Medical Devices, the leading Ethics Committee of the University of Münster and the corresponding Ethics Committee at each participating site.Trial registration numberNCT02669589.


2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Violeta Knezevic ◽  
Tijana Azasevac ◽  
Gordana Strazmester Majstorovic ◽  
Mira Markovic ◽  
Igor Mitic

Abstract Background and Aims Critically ill patients with acute renal impairment (AKI) with a high risk of bleeding require treatment with one of the methods of continuous renal replacement (CRRT) with regional citrate anticoagulation (RCA) or without anticoagulation (NA). The aim of the study was to compare CRRT with RCA using calcium with CRRT in NA regimen. Method A clinical trial included 55 surgical and non-surgical patients with acute kidney injury and an episode of acute kidney injury in chronic kidney disease who were admitted to the Intensive Care Unit (ICU) during 2020. The patients were divided into two groups, RCA- CRRT with 39 and NA-CRRT with 16 patients. Demographic, clinical and lab data before and after CRRT, treatment parameters CRRT and outcomes were analyzed. Results RCA vs NA group did not differ significantly by gender (small, 71.79% vs 56.25%, p = 0.106) and age (56.53 ± 17.55 vs 45.75 ± 13.3, p = 0.220). The NA group had a significantly higher prevalence of liver disease as a reason for the ICU admission when compared to the other group (12.5% vs 0.00%, p = 0.024). The RCA group before CRRT had significantly higher mean values of CRP (173.68 ± 122.06 vs 86.33 ± 51.05, p = 0.01) and significantly lower mean values of total bilirubin (16.78 ± 4.31 vs 40.02 ± 9.22, p = 0.005) and creatinine (463.97 ± 36.24 vs 486.0 ± 36.25, p = 0.001), while after CRRT it had significantly higher average values of total calcium (2.12 ± 0.016 vs 2.11 ± 0.017, p = 0.023) and lower average values of pH (7.29 ± 0.02 vs 7.32 ± 0.015, p = 0.040) and creatinine (463.97 ± 36.24 vs 486.0 ± 36.25, p = 0.001) in relation to the NA group. No significant difference was found in relation to invasive mechanical ventilation, vasopressors therapy, SAPS II score, oliguria / anuria, recovery of renal function, the length of hospital stay and mortality (p&gt; 0.05) (Table 1). Compared to treatment parameters, the RCA group had a significantly lower number of procedures (4.33 ± 2.80 vs 5.81 ± 1.28, p = 0.027) and ultrafiltration rate (2.79 ± 0.19 vs 3.14 ± 0.33, p = 0.015) and significantly longer hemofilter lifespan compared to NA group (24.64 ± 0.48 vs 18.10 ± 0.58, p = 0.000). Although the prevalence of bleeding was higher in the NA group, no significant difference was found between the groups (37.5% vs 28.20%, p = 0.498), as well as in the infusion of red blood cell (33.3% vs 37.5%, p = 0.768), fresh frozen plasma (28.2% vs 50%, p = 0.742) and platelets (35.89 vs 31.25, p = 0.123). The overall citrate accumulation (CA&gt; 2.25) rate was 5.12% in the RCA group (Table 2). The Kaplan-Meier survival analysis using the log-rank test (Mantel-Cox test) for comparing the hemofilter lifespan between RCA and NA regime found a significant difference in survival between the groups (χ2 = 3,789, p = 0,049) (Figure 1). Multiple regression model for testing risk factors SAPS II score, Oxiris membrane, UF, lactate, hemoglobin concentration, platelet count, Activated Partial Thromboplastin Time and Prothrombin Time on hemofilter survival has shown a significant linear relationship without statistical significance in both RCA groups (R=0.544 ; F=1.575) and NA (R=0.757; F=1.171) (Table 3). Conclusion RCA-CRRT did not show a significant difference in the prevalence of bleeding compared to NA-CRRT in the patients with a high risk of bleeding, but the survival rate of hemofilters was significantly longer in RCA-CRRT, which suggested the need for further research.


2019 ◽  
Vol 43 (1) ◽  
pp. 10-16
Author(s):  
Thomas Dimski ◽  
Timo Brandenburger ◽  
Torsten Slowinski ◽  
Detlef Kindgen-Milles

Introduction: Septic shock is characterized by severe metabolic and hemodynamic alterations. It is often accompanied by acute kidney injury. A new adjunct treatment is hemoadsorption using a cytokine adsorber in line with continuous veno-venous renal replacement therapy. We studied the feasibility, efficacy, and safety of cytokine adsorption with citrate-anticoagulated continuous veno-venous hemodialysis (regional citrate anticoagulation–continuous veno-venous hemodialysis). Methods: In 11 patients with septic shock and acute kidney injury stage 3, we studied 12 cycles of cytokine adsorption and regional citrate anticoagulation–continuous veno-venous hemodialysis. We monitored parameters of citrate anticoagulation, circuit lifetime, laboratory parameters, hemodynamics, and vasopressor demand. Results: Ten out of 12 adsorber/continuous veno-venous hemodialysis circuits reached the target lifetime of 24 h for the adsorber. One system clotted and one was stopped for non-device-related reasons. Nine of the remaining continuous renal replacement therapy circuits reached 72 h lifetime. With default settings for regional citrate anticoagulation, serum ionized calcium and pH were in the normal range. Urea and creatinine were reduced significantly, and norepinephrine dose decreased from 0.47 (±0.09) to 0.16 (±0.04) µg/kg/min ( p = 0.016) after 24 h. Discussion: We show that combined cytokine adsorption/continuous veno-venous hemodialysis is effective to control pH, to reduce urea and creatinine, and to improve hemodynamics by reducing norepinephrine doses in patients with septic shock. It can be applied safely with standard settings of regional citrate anticoagulation rendering sufficiently long filter lifetimes for the adsorber and the continuous veno-venous hemodialysis circuit. Further studies are on the way to investigate whether these effects translate into improved outcomes in septic shock patients.


Sign in / Sign up

Export Citation Format

Share Document